Effect and mechanism of FGF21 on astrocyte damage induced by Aβ<sub>25-35</sub>

SUN Yan; GAO Xiangdong; CHEN Song

doi:10.11665/j.issn.1000-5048.20190415

Journal of China Pharmaceutical University > 2019 > 50(4): 490-496. > DOI: 10.11665/j.issn.1000-5048.20190415

SUN Yan, GAO Xiangdong, CHEN Song. Effect and mechanism of FGF21 on astrocyte damage induced by Aβ_25-35[J]. Journal of China Pharmaceutical University, 2019, 50(4): 490-496. DOI: 10.11665/j.issn.1000-5048.20190415

Citation:

PDF (3192 KB)

Effect and mechanism of FGF21 on astrocyte damage induced by Aβ_25-35

More Information

Graphical Abstract

Abstract

Abstract

To investigate the effects and mechanism of fibroblast growth factor 21(FGF21)on astrocytes in AD-like lesions, Aβ_25-35 was used to induce astrocyte model damaged. Cell model was established by inducing C6 astrocyte cell line and primary astrocyte damage with Aβ_25-35_.Different concentrations of FGF21 were used to intervene cell injury model induced by Aβ_25-35, and cell viabilities were detected by MTT assay. Effects of FGF21 and Aβ_25-35 on reactive oxygen species(ROS)levels in C6 cells were tested using DCFH-DA probe and flow cytometry. Western blot was used to assess the effects of FGF21 and Aβ_25-35 on the activities of mitogen-activated protein kinases(MAPKs)in C6 cells. The results showed that FGF21 could reduce the damage of C6 cells and primary astrocytes induced by Aβ_25-35, down-regulate the abnormal ROS level in C6 cells, and alleviate the abnormal phosphorylation levels of MEK1/2, ERK1/2 and p38 in C6 cells induced by Aβ_25-35, suggesting that FGF21 may attenuate Aβ_25-35-induced astrocyte damage by regulating ROS pathway and MAPKs signaling pathway.
- fibroblast growth factor 21,
- Alzheimer′s disease,
- astrocytes,
- reactive oxygen species,
- mitogen-activated protein kinases

FullText(HTML)

References (21)

References

[1]	Cheignon C,Tomas M,Bonnefont-Rousselot D,et al.Oxidative stress and the amyloid beta peptide in Alzheimer′s disease[J].Redox Biol,2018,14:450-464.
[2]	Scheltens P,Blennow K,Breteler MMB,et al.Alzheimer′s disease[J].Lancet,2016,388(10043):505-517.
[3]	Jahanshahi M,Sadeghi Y,Hosseini A,et al.The effect of spatial learning on the number of astrocytes in the CA3 subfield of the rat hippocampus[J].Singapore Med J,2008,49(5):388-391.
[4]	Suzuki A,Stern SA,Bozdagi O,et al.Astrocyte-neuron lactate transport is required for long-term memory formation[J].Cell,2011,144(5):810-823.
[5]	Kawano H,Oyabu K,Yamamoto H,et al.Astrocytes with previous chronic exposure to amyloid β-peptide fragment 1-40 suppress excitatory synaptic transmission[J].J Neurochem,2017,143(6):624-634.
[6]	Leszek J,Trypka E,Tarasov VV,et al.Type 3 diabetes mellitus:a novel implication of Alzheimer′s disease[J].Curr Top Med Chem,2017,17(12):1331-1335.
[7]	Giralt M,Gavaldà-Navarro A,Villarroya F.Fibroblast growth factor-21,energy balance and obesity[J].Mol Cell Endocrinol,2015,418(Pt 1):66-73.
[8]	Degirolamo C,Sabbà C,Moschetta A.Therapeutic potential of the endocrine fibroblast growth factors FGF19,FGF21 and FGF23[J].Nat Rev Drug Discov,2016,15(1):51-69.
[9]	Hsuchou H,Pan WH,Kastin AJ.The fasting polypeptide FGF21 can enter brain from blood[J].Peptides,2007,28(12):2382-2386.
[10]	Fon Tacer K,Bookout AL,Ding XS,et al.Research resource:comprehensive expression atlas of the fibroblast growth factor system in adult mouse[J].Mol Endocrinol,2010,24(10):2050-2064.
[11]	Sa-Nguanmoo P,Tanajak P,Kerdphoo S,et al.FGF21 improves cognition by restored synaptic plasticity,dendritic spine density,brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats[J].Horm Behav,2016,85:86-95.
[12]	Chen ST,Chen S,Gao XD.Construction,expression,purification and neuroprotective activity of TAT-FGF21 fusion protein[J].J China Pharm Univ(中国药科大学学报),2018,49(4):496-501.
[13]	Jack CR Jr,Knopman DS,Jagust WJ,et al.Hypothetical model of dynamic biomarkers of the Alzheimer′s pathological cascade[J].Lancet Neurol,2010,9(1):119-128.
[14]	Selkoe DJ.Alzheimer disease:mechanistic understanding predicts novel therapies[J].Ann Intern Med,2004,140(8):627-638.
[15]	Selkoe DJ,Hardy J.The amyloid hypothesis of Alzheimer′s disease at 25 years[J].EMBO Mol Med,2016,8(6):595-608.
[16]	Poprac P,Jomova K,Simunkova M,et al.Targeting free radicals in oxidative stress-related human diseases[J].Trends Pharmacol Sci,2017,38(7):592-607.
[17]	Cheignon C,Tomas M,Bonnefont-Rousselot D,et al.Oxidative stress and the amyloid beta peptide in Alzheimer′s disease[J].Redox Biol,2018,14:450-464.
[18]	Rodríguez-Arellano JJ,Parpura V,Zorec R,et al.Astrocytes in physiological aging and Alzheimer′s disease[J].Neuroscience,2016,323:170-182.
[19]	Wang K,Yao Y,Zhu X,et al.Amyloid β induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase-and mitochondria-dependent ROS production[J].J Biochem Mol Toxicol,2017,31(6):e21887.
[20]	Xu Z,Chen S,Wang Y,et al.Neuroprotective effects of silk fibroin hydrolysate against Aβ25-35 induced cytotoxicity in SH-SY5Y cells and primary hippocampal neurons by regulating ROS inactivation of PP2A[J].J Funct Foods,2018,45:100-109.
[21]	Kirouac L,Rajic AJ,Cribbs DH,et al.Activation of ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer′s disease[J].eNeuro,2017,4(2).pii:ENEURO.0149-16.2017.

[1]	LI Hongxue, ZHANG Lei. Analysis of patent applications of heterocyclic compounds in China Pharmaceutical University 2010-2014[J]. Journal of China Pharmaceutical University, 2016, 47(2): 247-250. DOI: 10.11665/j.issn.1000-5048.20160220
[2]	MAO Dan. Patent analysis of pharmaceutical cocrystals technology in China[J]. Journal of China Pharmaceutical University, 2015, 46(4): 509-512. DOI: 10.11665/j.issn.1000-5048.20150421
[3]	WANG Jingjing, WANG Huiyan, ZHANG Lingling, XIAO Jing, HU Weiguo, ZHANG Caixia, ZHOU Jie. Technical analysis of low molecule weight heparins patents and R&D suggestions[J]. Journal of China Pharmaceutical University, 2015, 46(4): 504-508. DOI: 10.11665/j.issn.1000-5048.20150420
[4]	X-Ray Diffraction Fourier Fingerprint Pattern Analysis for Qingkailing Patent Medicine[J]. Journal of China Pharmaceutical University, 2004, (2): 41-43.
[5]	Study on Related Substances and Stability of Ceftazidime and its Preparation[J]. Journal of China Pharmaceutical University, 2002, (2): 35-38.
[6]	System Separation of Cyclosporin A Triple Therapeutic Drugs by Micellar Electrokinetic Capillary Chromatography and Evaluation of Optimal Method Ruggedness[J]. Journal of China Pharmaceutical University, 1999, (5): 373-376.
[7]	HPLC Analysis of Metoprolol and Its Metabolites in the Perfusates[J]. Journal of China Pharmaceutical University, 1997, (6): 31-35.
[8]	NMR Analysis of Bromocriptine Mesilate Tenoxicam[J]. Journal of China Pharmaceutical University, 1997, (5): 33-35.
[9]	Studies on the Synthesis and Analysis of Impurities and Decomposition Product of Ondansetron Hydrochlorid[J]. Journal of China Pharmaceutical University, 1997, (4): 8-10.
[10]	The Preparation and Analysis of New Sweetener L-Asp-D-Ala-OiPr[J]. Journal of China Pharmaceutical University, 1997, (2): 114-115.

Cited By

Get Citation

PDF

XML

Article views (475) PDF downloads (787)

Turn off MathJax

Article Contents

Abstract

References

Effect and mechanism of FGF21 on astrocyte damage induced by Aβ_25-35

Abstract

References

Related Articles

Catalog

Effect and mechanism of FGF21 on astrocyte damage induced by Aβ25-35

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content

Effect and mechanism of FGF21 on astrocyte damage induced by Aβ_25-35